Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,6 GBX | +2,00% |
|
-2,44% | -6,28% |
07/05 | Koersdoel AstraZeneca verhoogd; Antofagasta verlaagd | AN |
2023 | Synairgen benoemt Phytome's Joseph Colliver tot CFO | AN |
Vakgebied
Aantal werknemers: 34
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Marsden
CEO | Chief Executive Officer | 57 | 01-11-03 |
Joseph Colliver
DFI | Director of Finance/CFO | 43 | 06/11 |
Marcin Mankowski
CTO | Chief Tech/Sci/R&D Officer | - | 03-10-23 |
Jody Brooks
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-04 |
Phillip Monk
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-10-06 |
Richard Hennings
PRN | Corporate Officer/Principal | - | 01-03-21 |
Helen Gearing
PRN | Corporate Officer/Principal | - | 01-12-21 |
Gareth Walters
LAW | General Counsel | - | 13-10-21 |
Richard Francis
PRN | Corporate Officer/Principal | - | 01-09-21 |
Simon Holden
SEC | Corporate Secretary | 48 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Simon Shaw
CHM | Chairman | 59 | 01-06-03 |
Stephen Holgate
FOU | Founder | 77 | 01-06-03 |
Richard Marsden
CEO | Chief Executive Officer | 57 | 01-11-03 |
David Campbell
BRD | Director/Board Member | 80 | 11-04-06 |
Felicity Gabbay
BRD | Director/Board Member | 72 | 29-09-22 |
Phillip Monk
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-10-06 |
Amanda Radford
BRD | Director/Board Member | 53 | 01-12-22 |
Joseph Colliver
DFI | Director of Finance/CFO | 43 | 06/11 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 201 374 975 | 195 196 912 ( 96,93 %) | 0 | 96,93 % |
Bedrijfsgegevens
Synairgen Plc
Mailpoint 810 Southampton General Hospital
SO16 6YD, Southampton
+44 23 8051 2800
http://www.synairgen.com![Adres Synairgen plc(SNG)](https://cdn.zonebourse.com/static/address/4004905.png)
Sector
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-6,28% | 14,03 mln. | |
+38,36% | 52,5 mld. | |
+36,73% | 39,31 mld. | |
-8,63% | 39,01 mld. | |
+25,46% | 28,2 mld. | |
-11,17% | 26,57 mld. | |
+11,44% | 26,2 mld. | |
+45,09% | 14,15 mld. | |
+32,93% | 12,62 mld. | |
-5,30% | 11,74 mld. |